Fusion Pharmaceuticals’ new facility at McMaster Innovation Park (MIP) will support the research, development and production of next-generation radiopharmaceuticals for the treatment of various cancers.
Demand from investors raised the opening share price from earlier predictions, a strong indication of confidence in Fusion's potential to create new cancer therapies using nuclear medicine.
The day-long event outlined the journey from academic discovery to commercial development, highlighting recent startup successes at McMaster
McMaster logo
McMaster logo
